{"doi":"10.1016/j.amjcard.2011.06.045","title":"Comparison of Mortality and Morbidity in Patients With Atrial Fibrillation and Heart Failure With Preserved Versus Decreased Left Ventricular Ejection Fraction","abstract":null,"journal":"The American Journal of Cardiology","year":2011,"id":653779,"datarank":3.2198992150538746,"base_score":3.9512437185814275,"endowment":3.9512437185814275,"self_citation_contribution":0.5926865577872142,"citation_network_contribution":2.6272126572666603,"self_endowment_contribution":0.5926865577872142,"citer_contribution":2.6272126572666603,"corpus_percentile":null,"corpus_rank":null,"citation_count":51,"citer_count":49,"citers_with_citation_signal":46,"citers_with_endowment":46,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1705920,"name":"Ankit Rathod","orcid":null,"position":1,"is_corresponding":false},{"id":1705921,"name":"Mohammad A. Kizilbash","orcid":null,"position":2,"is_corresponding":false},{"id":1705922,"name":"Aditya Bhardwaj","orcid":null,"position":3,"is_corresponding":false},{"id":1705923,"name":"Omaima Ali","orcid":null,"position":4,"is_corresponding":false},{"id":1679599,"name":"Luis Afonso","orcid":null,"position":5,"is_corresponding":false},{"id":1666821,"name":"Sony Jacob","orcid":null,"position":6,"is_corresponding":false},{"id":1705919,"name":"Apurva O. Badheka","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Comparison of Mortality and Morbidity in Patients With Atrial Fibrillation and Heart Failure With Preserved Versus Decreased Left Ventricular Ejection Fraction","abstract":"Almost 50% of patients with congestive heart failure (HF) have preserved ejection fraction (PEF). Data on the effect of HF-PEF on atrial fibrillation outcomes are lacking. We assessed the prognostic significance of HF-PEF in an atrial fibrillation population compared to a systolic heart failure (SHF) population. A post hoc analysis of the National Heart, Lung, and Blood Institute-limited access data set of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was carried out. The patients with a history of congestive HF and a preserved ejection fraction (EF >50%) were classified as having HF-PEF (n = 320). The patients with congestive HF and a qualitatively depressed EF (EF <50%) were classified as having SHF (n = 402). Cox proportional hazards analysis was performed. The mean follow-up duration was 1,181 ± 534 days/patient. The patients with HF-PEF had lower all-cause mortality (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.46 to 0.85, p = 0.003) and cardiovascular mortality (HR 0.56, 95% CI 0.38 to 0.84, p = 0.006), with a possible decreased arrhythmic end point (HR 0.39, 95% CI 0.16 to 1.006, p = 0.052) than did the patients with SHF. No differences were observed for ischemic stroke (HR 1.08, 95% CI 0.48 to 2.39, p = 0.86), rehospitalization (HR 0.89, 95% CI 0.75 to 1.07, p = 0.24), or progression to New York Heart Association class III-IV (odds ratio 0.80, 95% CI 0.42 to 1.54, p = 0.522). In conclusion, although patients with HF-PEF have better mortality outcomes than those with SHF, the morbidity appears to be similar.","is_dataset_classified":null,"base_score":3.9512437185814275,"endowment":3.9512437185814275,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21855829","pmcid":null,"openalex_id":"https://openalex.org/W2035069710","authors":[],"funders":[],"total_grants":0,"fwci":3.143,"citation_percentile":0.92234691,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":3},{"year":2014,"count":10},{"year":2015,"count":5},{"year":2016,"count":6},{"year":2017,"count":2},{"year":2018,"count":2},{"year":2019,"count":1},{"year":2020,"count":4},{"year":2021,"count":5},{"year":2022,"count":4},{"year":2023,"count":3},{"year":2024,"count":1},{"year":2025,"count":2}],"oa_status":"closed","license":"https://www.elsevier.com/tdm/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0002914911022375?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0002914911022375?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.amjcard.2011.06.045","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/21855829","host_type":"repository"}],"fields_of_study":["Atrial Fibrillation Management and Outcomes","Cardiovascular Function and Risk Factors","Heart Failure Treatment and Management","Age Factors","Aged","Anticoagulants","Atrial Fibrillation","Disease Progression","Female","Heart Failure","Humans","Hypertension","Male","Patient Readmission","Prognosis","Proportional Hazards Models","Randomized Controlled Trials as Topic","Sex Factors","Stroke","Stroke Volume","United States","Warfarin"],"mesh_terms":["Age Factors","Aged","Anticoagulants","Atrial Fibrillation","Female","Heart Failure","Humans","Hypertension","Male","Patient Readmission","Prognosis","Sex Factors","Stroke Volume","United States","Warfarin","Proportional Hazards Models","Randomized Controlled Trials as Topic","Disease Progression","Stroke"],"keywords":["Medicine","Cardiology","Heart failure","Internal medicine","Atrial fibrillation","Ejection fraction","Hazard ratio","Population","Odds ratio","Confidence interval","Proportional hazards model","Stroke (engine)"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T00:40:07.123304Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}